Search
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51339] It was also approved by the EMA on May 30, 2017 [L51324] and by Health Canada on December 19, 2018. … Cerliponase alfa is a hydrolytic lysosomal N-terminal tripeptidyl peptidase-1 (TPP1).
Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl PeptidaseTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalT-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. … Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic
AV608
go.drugbank.com/drugs/DB05072InvestigationalAV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
Secretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalPurified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S..
Teplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigational[A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients … Although the mechanism of action of teplizumab has not been fully elucidated, it may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes.
Torasemide
go.drugbank.com/drugs/DB00214ApprovedInvestigational[A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]
Categories: Non Potassium Sparing DiureticsSynonyms: N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamideOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145] … [L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalTherapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999]. … For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999].
Nedaplatin
go.drugbank.com/drugs/DB13145ApprovedInvestigationalIt is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.